NCT01066156

Post-Traumatic Stress Disorder (PTSD) and Seroquel

Functional Reciprocity Between Heightened Stress Reactivity and Emotional Numbing in PTSD: Novel Predictors of Pharmacotherapeutic Outcomes

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Cambridge Health Alliance · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This 8 weeks study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD.

Detailed description

An initial telephone interview will be conducted to determine if potential subjects meet the basic study requirements. If no obvious counterindications are present, subjects will be scheduled for a screening visit. After briefing the subjects on the reasons for the research, they will be given an opportunity to read the Informed Consent Form, approved by the Cambridge Health Alliance Institutional ReviewBoard, and to ask questions prior to signing it. Subjects will be given a copy of the signed Consent Form. Each subject will complete a standardized interview schedule designed to obtain personal and background data along with psychodiagnostic and psychometric evaluations. An open-label treatment will be utilized for all patients. Seroquel tablets will be flexibly dosed and begun at a target dose of 25 mg per day and taken over an 8 week period.

Conditions

• Post-Traumatic Stress Disorder

Interventions

Type	Name	Description
DRUG	Seroquel	This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD

Timeline

• Start date: 2010-02-01
• Primary completion: 2015-03-01
• Completion: 2015-03-01
• First posted: 2010-02-10
• Last updated: 2017-05-30
• Results posted: 2017-05-30

Locations

1 site across 1 country: United States